Immunovant, Inc. (IMVT) Financials
NASDAQ:IMVTMarket Cap
2.81B
| Metric | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| -- | -- | -- | -- | |
| -- | -- | -- | -- | |
| -- | -- | -- | -- | |
| 47,927,000 | 68,604,000 | 101,808,000 | 160,257,000 | |
| -- | -- | -- | -- | |
| 18,151,000 | 39,513,000 | 54,225,000 | 48,019,000 | |
| 18,151,000 | 39,513,000 | 54,225,000 | 48,019,000 | |
| 66,078,000 | 108,117,000 | 156,033,000 | 208,276,000 | |
| -65,666,000 | -107,789,000 | -156,159,000 | -198,469,000 | |
| -625,000 | 328,000 | -655,000 | -12,482,000 | |
| -65,645,000 | -107,724,000 | -156,033,000 | -198,276,000 | |
| 21,000 | 65,000 | 126,000 | 193,000 | |
| -- | -- | -- | 7,578,000 | |
| 625,000 | -- | 655,000 | 12,482,000 | |
| -66,291,000 | -107,789,000 | -156,814,000 | -210,951,000 | |
| 97,000 | -358,000 | -84,000 | 9,000 | |
| -66,388,000 | -107,431,000 | -156,730,000 | -210,960,000 | |
| -1.54 | -1.22 | -1.43 | -1.71 | |
| -1.54 | -1.22 | -1.43 | -1.71 | |
| 43,199,191 | 87,756,513 | 109,679,256 | 123,075,329 | |
| 43,199,191 | 87,756,513 | 109,679,256 | 123,075,329 | |
| 66,078,000 | 108,117,000 | 156,033,000 | 208,276,000 | |
| 412,000 | 328,000 | -781,000 | -253,000 |
Key Facts
Industry
Biotechnology
Sector
Healthcare
Headquarters
New York, NY, US
Website
CEO
Dr. Peter Salzmann M.B.A., M.D.
Employees
164
About the Company
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.